Alanex Ltd. Laboratories for Molecular Design of San Diegoannounced today the members of its newly created scientificadvisory board. They include: Floyd Bloom, chairman of thedepartment of Neuropharmacology at the Scripps ResearchInstitute; Palmer Taylor, professor and chairman of thedepartment of pharmacology at the University of California,San Diego (UCSD); Charles Perrin, professor of chemistry atUCSD; and Jean Rivier, professor of chemistry at the SalkInstitute.
Arris Pharmaceutical Corp. of South San Francisco, appointedJohn Walker its president and chief executive officer. Walkerjoins Arris from Alpha Venture Partners, a seed-stage fund forlife sciences.
Athena Neurosciences Inc. of South San Francisco has appointedTeresa Chuh as associate general counsel. She joins Athenafrom Charles Ferguson & Co., where she practiced corporatelaw.
BioCryst Pharmaceuticals Inc. of Birmingham, Ala., namedYuichi Iwaki to its scientific advisory board. Iwaki is theDirector at the National Institute of Transplantation, the MeticTransplantation Laboratory, Sharp Memorial Hospital'sTransplantation Laboratory and the University of SouthernCalifornia Transplantation Immunology and ImmunogeneticsLaboratory.
Cortex Pharmaceuticals Inc. of Irvine, Calif., appointed AlanSteigrod as president and chief executive officer, as well asgiving him a position on the board of directors. He was anexecutive vice president at Glaxo Inc.
Embrex Inc. of Research Triangle Park, N.C., elected LesterCrawford to its board of directors. Crawford is the formerdirector of the FDA's Center for Veterinary Medicine. Crawfordis also the executive vice president for scientific affairs at theNational Food Processors Association.
GalaGen Inc. of Arden Hills, Minn., elected Robert Hoerr as vicepresident, medical and regulatory affairs and Peter Sadowskias senior research scientist. Hoerr had been director, medicalaffairs for Sandoz Nutrition Corp. in Minneapolis. Sadowskicame from American Biosystems Inc, located in Stillwater,Minn., where he held the position of vice president, researchand development.
Genelabs Technologies Inc. of Redwood City, Calif., appointedThomas Fuerst as vice president of vaccine research anddevelopment for Genelabs' San Antonio, Texas, facility. Fuersthad been the director of molecular genetics at Gaithersburg,Md., firm MedImmune Inc.
Glycomed Inc. of Alameda, Calif., announced that MaryTreuhaft had joined the company as senior director ofregulatory affairs. She had been the associate director ofregulatory affairs at Schering Plough Research, Kenilworth, N.J.
Ixsys Inc. of San Diego appointed Michael Palladino as vicepresident, preclinical development. Prior to joining Ixsys,Palladino was the director of cell biology at Genentech, Inc.
MedClone Inc. of Los Angeles announced that Sir Aaron Klughas joined its scientific advisory board. Klug received the 1982Nobel Prize in chemistry for developing methods, includingcrystallographic electron microscopy, to determine thestructure of biologically important molecular complexes such asviruses.
Neocrin Co. of Irvine, Calif., appointed Anita Beck as director ofmedical affairs. Beck had positions in the regulatorydepartments at Vestar Inc. and Viratek Inc. Neocrin also addedHarvey Sadow and Dennis Donahue to its board of directors.Sadow has been board chairman for Boehringer IngelheimCorp. and Boehringer Ingelheim Pharmaceuticals Inc., CortexPharmaceuticals, Cholestech Corp., Delta Health ProductsDevelopment Corp. and Roxane Laboratories Inc. Donahue heldpositions as associate director at FDA's Center for Drugs andBiologics and director of the agency's Division of Blood andBlood Products.
Quidel Corp. of San Diego appointed Mary Lake Polan to itsboard of directors. She presently serves as chairman,department of gynecology and obstetrics at Stanford Universityof Medicine.
Scios Nova Inc. of Mountain View, Calif., elected William Millerand Eugene Step to its board of directors. Miller is a professorof public and private management and a professor of computerscience at Stanford University. He is also president emeritus atSRI International. Step recently retired as executive vicepresident, president of the pharmaceuticals division and amember of the board of directors and executive committee ofEli Lilly and Co.
Synergen Inc. of Boulder, Colo., has promoted two of itsdirectors. Paul Hastings becomes the vice president ofmarketing and sales and Geoffrey Slaff becomes the vicepresident of process engineering. .TSI Corp. of Worcester, Mass.announced three management appointments to reconfigure itslife sciences and biologics operations. Cary Garner, senior vicepresident, will direct the company's U.S. life sciences group.Paul Morrison will head TSI Europe Ltd. and Lisa Pisano, seniorvice president, will direct the company's biologics unit, TSIBiologics.
(c) 1997 American Health Consultants. All rights reserved.